A few days back the Indian Patent Office revoked the patent of Novartis’ ‘blockbuster’ fixed dose combination cardiac drug, sacubitril-valsartan marketed under the trade name Vymada citing ‘lack of novelty and inventive step’ according to an Indian media report.